Patient-focused migraine management: Establishing needs

Drugs of Today

Volumn 39, Issue SUPPL. D, 2003, Pages 3-9

  Dodick, David W ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ALLODYNIA; CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HEALTH CARE NEED; HUMAN; MIGRAINE; NAUSEA; PATIENT ATTITUDE; PATIENT FOCUSED THERAPY; PATIENT SATISFACTION; PHOTOPHOBIA; QUALITY OF LIFE; SIDE EFFECT; UNITED STATES;

HUMANS; MIGRAINE DISORDERS;

EID: 1442324854     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. World Health Organization. Headache Disorders and Public Health. WHO, Geneva, Switzerland, 2000.
2. World Health Organization. The World Health Report 2001.
3. Clarke, C.E., MacMillan, L., Sondhi, S., Wells, N.E.J. Economic and social impact of migraine. Q J Med 1996, 89: 77-84.
4. Lipton, R.B., Stewart, W.F., Von Korff, M. Migraine impact and functional disability. Cephalalgia 1995, 15(Suppl. 15): 4-9.
5. Headache Classification Committee of the International Headache Society. Classification and Diagnostic Criteria for Headache Disorders, Cranial Neuralgias and Facial Pain. B. Stougaard Jensen, Copenhagen, Denmark, 1988, 19-20.
6. Lipton, R.B., Diamond, S., Reed, M., Diamond, M.L., Stewart, W.F. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001, 41: 638-45.
7. Lipton, R.B., Stewart, W.F. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999, 39: S20-6.
8. Lipton, R.B., Stewart, W.F., Diamond, S., Diamond, M.L., Reed, M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001, 41: 646-57.
9. MacGregor, E.A., Brandes, J., Eikermann, A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey headache. Headache 2003, 43: 19-26.
10. Lipton, R.B., Dodick, D.W., Sadovsky, R. et al. A self-administered screener for migraine in primary care: The ID migraine™ validation study. Neurology 2003, 61: 375-82.
11. Ferrari, M.D., Roon, K.I., Lipton, R.B., Goadsby, P.J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001, 358: 1668-75.
12. Ferrari, M.D. Tripstar: A comprehensive patient-based approach to compare triptans. Headache 2002, 42(Suppl. 1): 18-25.
13. Gallagher, R.M., Kunkel, R. Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache 2003, 43: 36-43.
14. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998, 38: 173-83.
15. Pascual, J., Cabarrocas, X. Within patient early versus delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache 2002, 42: 28-31.
16. Mathew, N.T. on behalf of Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache 2002, 42: 32-40.
17. Burstein, R., Cutrer, M.F., Yarnitsky, D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123: 1703-9.
18. Burstein, R., Collins, B., Bajwa, Z., Jukubowski, M. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: Clinical and preclinical evidence. Headache 2002, 42: 390-1.